| 1.39 0.1 (7.75%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.69 | 1-year : | 1.97 |
| Resists | First : | 1.45 | Second : | 1.69 |
| Pivot price | 1.33 |
|||
| Supports | First : | 1.23 | Second : | 1.1 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.31 |
| MA(100) : | 2.05  |
MA(250) : | 5.88 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 47.8 |
D(3) : | 55.7 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 18.89 | Low : | 1 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ OGEN ] has closed below upper band by 19.7%. Bollinger Bands are 86.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 59 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 1.27 - 1.28 | 1.28 - 1.29 |
| Close: | 1.37 - 1.39 | 1.39 - 1.4 |
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Tue, 07 Oct 2025
Press Telegram - FinancialContent
Tue, 07 Oct 2025
Oragenics (OGEN) Collaborates with Receptor.AI for Drug Developm - GuruFocus
Tue, 07 Oct 2025
Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development - Stock Titan
Tue, 02 Sep 2025
Oragenics appoints Natasha Giordano to board of directors - Investing.com
Tue, 01 Jul 2025
Oragenics (OGEN) Announces $20M Stock Placement Deal - GuruFocus
Tue, 01 Jul 2025
Oragenics, Inc. Announces $20 Million Public Offering of Series H Convertible Preferred Stock and Warrants - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 4.72e+006 (%) |
| Held by Institutions | 12 (%) |
| Shares Short | 43 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.964e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -263 % |
| Return on Assets (ttm) | 285.1 % |
| Return on Equity (ttm) | -219.9 % |
| Qtrly Rev. Growth | 7470 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -947.34 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -7.4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -13.35 |
| Dividend | 0 |
| Forward Dividend | 1.32e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|